Sign In
Buy ATNM
$0.84
-0.0001 (-0.0119%)
At Close: Jul 31, 2026
Maxim Group Releases a Hold Rating on Gilead Sciences (GILD)
12:51pm, Saturday, 18'th Apr 2020
Maxim Group analyst Jason McCarthy assigned a Hold rating to Gilead Sciences (GILD – Research Report) today. The company’s shares
Atossa Genetics (ATOS) Receives a Buy from Maxim Group
04:47pm, Friday, 17'th Apr 2020
In a report released today, Jason McCarthy from Maxim Group reiterated a Buy rating on Atossa Genetics (ATOS), with a price target of $4.00. The company's
Atossa Genetics (ATOS) Receives a Buy from Maxim Group
04:47pm, Friday, 17'th Apr 2020
In a report released today, Jason McCarthy from Maxim Group reiterated a Buy rating on Atossa Genetics (ATOS – Research
Analysts Are Bullish on These Healthcare Stocks: Eagle Pharmaceuticals (EGRX), Actinium Pharmaceuticals (ATNM)
02:27pm, Friday, 17'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eagle Pharmaceuticals (EGRX) and Actinium Pharmaceuticals
Analysts Are Bullish on These Healthcare Stocks: Eagle Pharmaceuticals (EGRX), Actinium Pharmaceuticals (ATNM)
02:27pm, Friday, 17'th Apr 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eagle Pharmaceuticals
Maxim Group Gives a Buy Rating to Actinium Pharmaceuticals (ATNM)
02:06pm, Friday, 17'th Apr 2020
In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to Actinium Pharmaceuticals (ATNM), with a price target of $1.50. The
Actinium Provides Update on Iomab-B SIERRA Trial and Expected Topline Results from Ad Hoc Analysis in 2020
11:00am, Thursday, 16'th Apr 2020
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today provided an update on the Iomab-B pivotal SIERRA (Study of Iomab-B in Elderly Relapse or Refractory Acute Myelo
Analysts Are Bullish on These Healthcare Stocks: Moleculin Biotech (MBRX), Axonics Modulation Technologies (AXNX)
07:07pm, Wednesday, 15'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Moleculin Biotech (MBRX) and Axonics Modulation
Analysts Are Bullish on These Healthcare Stocks: Moleculin Biotech (MBRX), Axonics Modulation Technologies (AXNX)
07:07pm, Wednesday, 15'th Apr 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Moleculin Biotech (
MBRX
–
Research Report
) and Axonics Modulation Technologies (
AXNX
–
Research
Can Actinium Pharmaceuticals (NYSEMKT:ATNM) Afford To Invest In Growth?
01:02pm, Sunday, 12'th Apr 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Aridis Pharmaceuticals (ARDS) Receives a Buy from Maxim Group
02:12pm, Friday, 10'th Apr 2020
Maxim Group analyst Jason McCarthy assigned a Buy rating to Aridis Pharmaceuticals (ARDS) today and set a price target of $17.00. The company's shares
Aridis Pharmaceuticals (ARDS) Receives a Buy from Maxim Group
02:12pm, Friday, 10'th Apr 2020
Maxim Group analyst Jason McCarthy assigned a Buy rating to Aridis Pharmaceuticals (ARDS – Research Report) today and set a
Moleculin Biotech (MBRX) Gets a Buy Rating from Maxim Group
03:04pm, Thursday, 09'th Apr 2020
In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to Moleculin Biotech (MBRX), with a price target of $3.00. The company's
Moleculin Biotech (MBRX) Gets a Buy Rating from Maxim Group
03:04pm, Thursday, 09'th Apr 2020
In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to Moleculin Biotech (MBRX – Research
